Literature DB >> 20407462

Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.

Maki Okada1, Ryuji Nakao, Rie Hosoi, Ming-Rong Zhang, Toshimitsu Fukumura, Kazutoshi Suzuki, Osamu Inoue.   

Abstract

The catecholamine, dopamine (DA), is synthesized from 3,4-dihydroxy-L-phenylalanine (L-DOPA) by aromatic L-amino acid decarboxylase (AADC). Dopamine metabolism is regulated by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). To measure dopaminergic metabolism, we used microdialysis with radiometric detection to monitor L-[β-(11)C]DOPA metabolites in the extracellular space of the rat striatum. We also evaluated the effects of AADC, MAO, and COMT inhibitors on metabolite profiles. The major early species measured after administration of L-[β-(11)C]DOPA were [(11)C]3,4-dihydroxyphenylacetic acid ([(11)C]DOPAC) and [(11)C]homovanillic acid ([(11)C]HVA) in a 1:1 ratio, which shifted toward [(11)C]HVA with time. An AADC inhibitor increased the uptake of L-[β-(11)C]DOPA and L-3-O-methyl-[(11)C]DOPA and delayed the accumulation of [(11)C]DOPAC and [(11)C]HVA. The MAO and COMT inhibitors increased the production of [(11)C]3-methoxytyramine and [(11)C]DOPAC, respectively. These results reflect the L-DOPA metabolic pathway, suggesting that this method may be useful for assessing dopaminergic metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407462      PMCID: PMC3049477          DOI: 10.1038/jcbfm.2010.58

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  37 in total

1.  Halothane enhances dopamine metabolism at presynaptic sites in a calcium-independent manner in rat striatum.

Authors:  Y U Adachi; M Satomoto; H Higuchi; K Watanabe; S Yamada; T Kazama
Journal:  Br J Anaesth       Date:  2005-08-19       Impact factor: 9.166

2.  Monitoring dopamine in vivo by microdialysis sampling and on-line CE-laser-induced fluorescence.

Authors:  Minshan Shou; Carrie R Ferrario; Kristin N Schultz; Terry E Robinson; Robert T Kennedy
Journal:  Anal Chem       Date:  2006-10-01       Impact factor: 6.986

3.  Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[beta-11C]DOPA.

Authors:  Hiroshi Ito; Miho Ota; Yoko Ikoma; Chie Seki; Fumihiko Yasuno; Akihiro Takano; Jun Maeda; Ryuji Nakao; Kazutoshi Suzuki; Tetsuya Suhara
Journal:  Nucl Med Commun       Date:  2006-09       Impact factor: 1.690

4.  Self-administered heroin and cocaine combinations in the rat: additive reinforcing effects-supra-additive effects on nucleus accumbens extracellular dopamine.

Authors:  James E Smith; Conchita Co; Michael D Coller; Scott E Hemby; Thomas J Martin
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

5.  Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET.

Authors:  L H Lindström; O Gefvert; G Hagberg; T Lundberg; M Bergström; P Hartvig; B Långström
Journal:  Biol Psychiatry       Date:  1999-09-01       Impact factor: 13.382

6.  Simultaneous determination of biogenic monoamines in rat brain dialysates using capillary high-performance liquid chromatography with photoluminescence following electron transfer.

Authors:  Moon Chul Jung; Guoyue Shi; Laura Borland; Adrian C Michael; Stephen G Weber
Journal:  Anal Chem       Date:  2006-03-15       Impact factor: 6.986

Review 7.  Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

Authors:  Maria João Bonifácio; P Nuno Palma; Luís Almeida; Patrício Soares-da-Silva
Journal:  CNS Drug Rev       Date:  2007

8.  Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of L-[beta-11C]DOPA and its metabolites for the validation of positron emission tomography studies.

Authors:  K J Lindner; P Hartvig; J Tedroff; A Ljungström; P Bjurling; B Långström
Journal:  J Pharm Biomed Anal       Date:  1995-04       Impact factor: 3.935

Review 9.  Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Authors:  Hubert H Fernandez; Jack J Chen
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705

10.  DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study.

Authors:  M Ernst; A J Zametkin; J A Matochik; P H Jons; R M Cohen
Journal:  J Neurosci       Date:  1998-08-01       Impact factor: 6.167

View more
  9 in total

1.  In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Siobhan McCormick; Chenoa Mah; James E Holden; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

2.  A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.

Authors:  Anil Modak; Raymon Durso; Ephraim Josephs; David Rosen
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

3.  L-Tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and striatum of the rat.

Authors:  Zachary D Brodnik; Manda Double; Rodrigo A España; George E Jaskiw
Journal:  Neuropharmacology       Date:  2017-05-29       Impact factor: 5.250

4.  Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high-fat diet.

Authors:  S Luo; Y Zhang; M Ezrokhi; Y Li; T-H Tsai; A H Cincotta
Journal:  J Neuroendocrinol       Date:  2018-01       Impact factor: 3.627

5.  Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release.

Authors:  Anne S Berry; Vyoma D Shah; Daniella J Furman; Robert L White; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Mark D'Esposito; William J Jagust
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

6.  Early infant exposure to excess multivitamin: a risk factor for autism?

Authors:  Shi-Sheng Zhou; Yi-Ming Zhou; Da Li; Qiang Ma
Journal:  Autism Res Treat       Date:  2013-03-04

7.  Relation between dopamine synthesis capacity and cell-level structure in human striatum: a multi-modal study with positron emission tomography and diffusion tensor imaging.

Authors:  Hiroshi Kawaguchi; Takayuki Obata; Harumasa Takano; Tsuyoshi Nogami; Tetsuya Suhara; Hiroshi Ito
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

8.  Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Anna Lee; Matthew J Farrer; A Jon Stoessl; Vesna Sossi
Journal:  EJNMMI Res       Date:  2013-10-02       Impact factor: 3.138

Review 9.  Dendrimer-based contrast agents for PET imaging.

Authors:  Lingzhou Zhao; Xiangyang Shi; Jinhua Zhao
Journal:  Drug Deliv       Date:  2017       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.